Drugs that contain Dasabuvir Sodium; Ombitasvir, Paritaprevir, Ritonavir

1. List of Viekira Pak (copackaged) drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8501238 ABBVIE INC Anti-infective agents and uses thereof
Dec, 2028

(5 years from now)

US8188104 ABBVIE INC Anti-infective agents and uses thereof
May, 2029

(6 years from now)

US8642538 ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors
Sep, 2029

(6 years from now)

US8420596 ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors
Apr, 2031

(8 years from now)

US8691938 ABBVIE INC Anti-viral compounds
Apr, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8268349 ABBVIE INC Solid pharmaceutical dosage form
Aug, 2024

(1 year, 6 months from now)

US8399015 ABBVIE INC Solid pharmaceutical dosage form
Aug, 2024

(1 year, 6 months from now)

US9139536 ABBVIE INC Anti-infective agents and uses thereof
Nov, 2028

(5 years from now)

US9006387 ABBVIE INC Anti-viral compounds
Jun, 2030

(7 years from now)

US9044480 ABBVIE INC Compositions and methods for treating HCV
Apr, 2031

(8 years from now)

US8686026 ABBVIE INC Solid compositions
Jun, 2031

(8 years from now)

US8685984 ABBVIE INC Methods for treating HCV
Sep, 2032

(9 years from now)

US8466159 ABBVIE INC Methods for treating HCV
Sep, 2032

(9 years from now)

US8680106 ABBVIE INC Methods for treating HCV
Sep, 2032

(9 years from now)

US8492386 ABBVIE INC Methods for treating HCV
Sep, 2032

(9 years from now)

US9629841 ABBVIE INC Formulations of pyrimidinedione derivative compounds
Oct, 2033

(10 years from now)

US10201542 ABBVIE INC Formulations of pyrimidinedione derivative compounds
Oct, 2033

(10 years from now)

Market Authorisation Date: 19 December, 2014

Treatment: Treatment of hcv infection using dasabuvir; Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir, without ribavirin; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir with ribavirin.; Use of dasabuvir to inhibit viral replication for the treatment of hcv infection.

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic